Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, November 2012

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 6 publications that cite this research output.

6

The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.

Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran

Article in Health Economics Review (September 2023)

Revisión sistemática de evaluaciones económicas de candesartán frente a losartán para el tratamiento de la hipertensión arterial en Europa

Article in Economía de la Salud (December 2020)

The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of Hypertension

Article in Value in Health (October 2017)